Momenta Pharmaceuticals (Momenta Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Apr. 26, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals Forward Dividend Yield %?

As of today (2024-04-26), the Forward Annual Dividend Yield of Momenta Pharmaceuticals is 0.00%.

As of today (2024-04-26), the Trailing Annual Dividend Yield of Momenta Pharmaceuticals is 0.00%.

MNTA's Forward Dividend Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.88
* Ranked among companies with meaningful Forward Dividend Yield % only.

Momenta Pharmaceuticals's Dividends per Share for the three months ended in Jun. 2020 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Momenta Pharmaceuticals's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Momenta Pharmaceuticals's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's Forward Dividend Yield % falls into.

Momenta Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Momenta Pharmaceuticals (NAS:MNTA) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Momenta Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.momentapharma.com

Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.

Executives

Bruce Downey	director
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner	director	C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo	officer: SVP, Chief Medical Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon	officer: Chief Financial & Bus. Officer	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier	officer: Chief Mfg and Program Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello	officer: Chief HR and Inf. Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning	officer: Chief Scientific Officer	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan	director	1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska	officer: Chief Accounting Officer (PAO)	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler	director, officer: President & CEO